DAPT Trial Results To Be Reviewed By FDA: Does It Cut Heart Attack Risk In Stent Patients?

November 17, 2014 12:30 AM

1 0

The FDA is reviewing a clinical trial that found 30 months of dual antiplatelet blood-thinning therapy reduced the risk of heart attack and clot formation in stents, but increased the rate of non-cardiovascular death compared with 12 months of treatment.

The FDA is reviewing a clinical trial that found 30 months of dual antiplatelet blood-thinning therapy reduced the risk of heart attack and clot formation in stents, but increased the rate of non-cardiovascular death compared with 12 months of treatment.

Read more

To category page

Loading...